Association of repeated exposure to antibiotics with the development of pediatric crohn's disease - A nationwide, register-based Finnish case-control study

American Journal of Epidemiology

Volumn 175, Issue 8, 2012, Pages 775-784

  Virta, Lauri ^a   Auvinen, Anssi ^b,c   Helenius, Hans ^d   Huovinen, Pentti ^d,e   Kolho, Kaija Leena ^f  

^a SOCIAL INSURANCE INSTITUTION   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Anti infective agents; Case control studies; Child; Colitis, ulcerative; Crohn disease; Inflammatory bowel diseases

Indexed keywords

CEFALEXIN; CEPHALOSPORIN; MACROLIDE; METRONIDAZOLE; PENICILLIN G DERIVATIVE; PHENETICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TRIMETHOPRIM;

ANTIBIOTICS; CHILD HEALTH; DIGESTIVE SYSTEM DISORDER; DISEASE INCIDENCE; EPIDEMIOLOGY; POLLUTION EXPOSURE;

ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG REEXPOSURE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PURCHASING; RISK; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; INFANT; INTESTINES; LOGISTIC MODELS; MALE; REGISTRIES;

FINLAND;

EID: 84859728797     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr400     Document Type: Article

References (44)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423-439.
2. Armitage E, Drummond HE, Wilson DC, et al. Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol. 2001;13(12): 1439-1447. (Pubitemid 33151496)
3. Auvin S, Molinié F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric in- flammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr. 2005;41(1):49-55. (Pubitemid 40967355)
4. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424-1429. (Pubitemid 350181588)
5. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009;44(4):446-456.
6. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009; 58(11):1490-1497.
7. Lehtinen P, Ashorn M, Iltanen S, et al. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis. 2011;17(8):1778-1783.
8. Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut. 2005;54(3):357-363. (Pubitemid 40299091)
9. Aspberg S, Dahlquist G, Kahan T, et al. Fetal and perinatal risk factors for inflammatory bowel disease. Acta Paediatr. 2006; 95(8):1001-1004. (Pubitemid 44181224)
10. Innis SM, Jacobson K. Dietary lipids in early development and intestinal inflammatory disease. Nutr Rev. 2007;65(12): S188-S193.
11. Gearry RB, Richardson AK, Frampton CM, et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25(2):325-333.
12. Bernstein CN. Epidemiologic clues to inflammatory bowel disease. Curr Gastroenterol Rep. 2010;12(6):495-501.
13. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010;330(6012):1768-1773.
14. Tannock GW. The bowel microbiota and inflammatory bowel diseases. Int J Inflam. 2010;2010:954051. (doi:10.4061/2010/954051).
15. Mondot S, Kang S, Furet JP, et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis. 2011;17(1):185-192.
16. Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis. 2000;32(1):81-85. (Pubitemid 30102961)
17. Jernberg C, Löfmark S, Edlund C, et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66. (Pubitemid 46717132)
18. Lindgren M, Löfmark S, Edlund C, et al. Prolonged impact of a one-week course of clindamycin on Enterococcus spp. in human normal microbiota. Scand J Infect Dis. 2009;41(3): 215-219.
19. Gilat T, Hacohen D, Lilos P, et al. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol. 1987;22(8):1009-1024. (Pubitemid 17152843)
20. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci. 1994; 39(3):555-560. (Pubitemid 24137343)
21. Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut. 2004;53(2): 246-250. (Pubitemid 38125513)
22. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54.
23. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105(12): 2687-2692.
24. Hildebrand H, Malmborg P, Askling J, et al. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol. 2008;43(8): 961-966.
25. Niemelä H, Salminen K. Social Security in Finland. Helsinki, Finland: Social Insurance Institution (KELA), Finnish Centre for Pensions (ETK), Finnish Pension Alliance (TELA), and Finnish Ministry of Social Affairs and Health; 2006.
26. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86-94.
27. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. ATC/DDD Index 2012 [database]. Oslo, Norway: Norwegian Institute of Public Health; 2011. (http://www.whocc.no/atcddd/). (Accessed June 10, 2011).
28. Finnish Medicines Agency and Social Insurance Institution. Finnish Statistics on Medicines 2009 [in Finnish]. Helsinki, Finland: Finnish Medicines Agency and Social Insurance Institution; 2010.
29. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med. 1980;68(2):255-258. (Pubitemid 10168997)
30. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981-983. (Pubitemid 29246861)
31. Collett D. Modelling Binary Data. 2nd ed. London, United Kingdom: Chapman & Hall Ltd; 2002.
32. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307(6908):846-848. (Pubitemid 23281752)
33. Margolis DJ, Fanelli M, Hoffstad O, et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610-2616.
34. Amre DK, Lambrette P, Law L, et al. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am J Gastroenterol. 2006;101(5): 1005-1011. (Pubitemid 43725314)
35. Huovinen P. Bacteriotherapy: the time has come. BMJ. 2001; 323(7309):353-354. (Pubitemid 32762453)
36. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459): 579-587. (Pubitemid 40247914)
37. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43): 16731-16736.
38. Jia W, Whitehead RN, Griffiths L, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett. 2010;310(2):138-144.
39. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005; 129(3):827-836. (Pubitemid 41242675)
40. Hemminki K, Li X, Sundquist J, et al. Subsequent autoimmune or related disease in asthma patients: clustering of diseases or medical care? Ann Epidemiol. 2010;20(3):217-222.
41. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. Chest. 2007;131(6): 1753-1759. (Pubitemid 46981630)
42. Risnes KR, Belanger K, Murk W, et al. Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1,401 US children. Am J Epidemiol. 2011;173(3): 310-318.
43. Kilkkinen A, Virtanen SM, Klaukka T, et al. Use of antimicrobials and risk of type 1 diabetes in a population-based mother-child cohort. Diabetologia. 2006;49(1):66-70. (Pubitemid 43151615)
44. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455(7216):1109- 1113.